L Sewell1, S J Singh, J E A Williams, R Collier, M D L Morgan. 1. Pulmonary Rehabilitation Research Group, Institute for Lung Health, Department of Respiratory Medicine and Thoracic Surgery, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, UK. louise.sewell@uhl-tr.nhs.uk
Abstract
BACKGROUND: The evidence of benefit for pulmonary rehabilitation (PR) programmes is established. However, the optimal duration of a PR programme is not known. A randomised controlled trial was undertaken in patients with chronic obstructive pulmonary disease (COPD) to assess whether a 4 week PR programme was equivalent to our conventional 7 week PR programme at equivalent time points of 7 weeks and 6 months. METHODS:One hundred patients (56 men) with stable COPD of mean (SD) age 70 (8) years and forced expiratory volume in 1 second (FEV1) 1.13 (0.50) litres were randomised to either a 7 week (n = 50) or 4 week (n = 50) supervised PR programme. Patients were assessed at baseline, at completion of the supervised PR programme, and 6 months later. Patients randomised to the 4 week group were also assessed at the 7 week time point. Outcome measures were the Incremental Shuttle Walk Test, Endurance Shuttle Walk Test (ESWT), Chronic Respiratory Questionnaire-Self Reported, and the Breathing Problems Questionnaire. RESULTS: Forty one patients in each group completed the PR programme. Patients made significant within group improvements after supervised rehabilitation. There were no statistically significant differences between the groups for any other measure at the 7 week or 6 month time points, except that patients in the 4 week group attained higher ESWT times (mean difference 124 seconds (95% CI 17.00 to 232.16), p = 0.024) at the 7 week time point. CONCLUSIONS: A shortened 4 week supervised PR programme is equivalent to a 7 week supervised PR programme at the comparable time points of 7 weeks and 6 months.
RCT Entities:
BACKGROUND: The evidence of benefit for pulmonary rehabilitation (PR) programmes is established. However, the optimal duration of a PR programme is not known. A randomised controlled trial was undertaken in patients with chronic obstructive pulmonary disease (COPD) to assess whether a 4 week PR programme was equivalent to our conventional 7 week PR programme at equivalent time points of 7 weeks and 6 months. METHODS: One hundred patients (56 men) with stable COPD of mean (SD) age 70 (8) years and forced expiratory volume in 1 second (FEV1) 1.13 (0.50) litres were randomised to either a 7 week (n = 50) or 4 week (n = 50) supervised PR programme. Patients were assessed at baseline, at completion of the supervised PR programme, and 6 months later. Patients randomised to the 4 week group were also assessed at the 7 week time point. Outcome measures were the Incremental Shuttle Walk Test, Endurance Shuttle Walk Test (ESWT), Chronic Respiratory Questionnaire-Self Reported, and the Breathing Problems Questionnaire. RESULTS: Forty one patients in each group completed the PR programme. Patients made significant within group improvements after supervised rehabilitation. There were no statistically significant differences between the groups for any other measure at the 7 week or 6 month time points, except that patients in the 4 week group attained higher ESWT times (mean difference 124 seconds (95% CI 17.00 to 232.16), p = 0.024) at the 7 week time point. CONCLUSIONS: A shortened 4 week supervised PR programme is equivalent to a 7 week supervised PR programme at the comparable time points of 7 weeks and 6 months.
Authors: T L Griffiths; M L Burr; I A Campbell; V Lewis-Jenkins; J Mullins; K Shiels; P J Turner-Lawlor; N Payne; R G Newcombe; A A Ionescu; J Thomas; J Tunbridge; A A Lonescu Journal: Lancet Date: 2000-01-29 Impact factor: 79.321
Authors: Darcy D Marciniuk; Dina Brooks; Scott Butcher; Richard Debigare; Gail Dechman; Gordon Ford; Veronique Pepin; Darlene Reid; Andrew W Sheel; Micheal K Stickland; David C Todd; Shannon L Walker; Shawn D Aaron; Meyer Balter; Jean Bourbeau; Paul Hernandez; Francois Maltais; Denis E O'Donnell; Donna Bleakney; Brian Carlin; Roger Goldstein; Stella K Muthuri Journal: Can Respir J Date: 2010 Jul-Aug Impact factor: 2.409
Authors: Matthew Maddocks; Samantha S C Kon; Jane L Canavan; Sarah E Jones; Claire M Nolan; Alex Labey; Michael I Polkey; William D-C Man Journal: Thorax Date: 2016-06-12 Impact factor: 9.139